<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330200</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 113715-CS11</org_study_id>
    <nct_id>NCT00330200</nct_id>
  </id_info>
  <brief_title>Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of ISIS 113715 Monotherapy on Insulin Sensitivity, Glucose and Lipid Metabolism and Energy Expenditure in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin
      sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2
      diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor enrollment
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">May 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effects of ISIS 113715 on hepatic and peripheral insulin sensitivity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine the effect on whole body energy expenditure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the effects on fasting and postprandial glucose excursions</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the effects on hemoglobin A1c (HbA1c)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expand the safety and tolerability profile for ISIS 113715</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of ISIS 113715 on rates of basal and insulin stimulated whole body glycerol turnover</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of ISIS 113715 on insulin suppression of local rates of lipolysis (microdialysis)</measure>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 113715</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (post menopausal and/or surgically sterile)

          -  Aged 18 to 70 years

          -  Treatment na√Øve subjects with fasting blood glucose levels of 150-220 mg/dL,
             hematocrit of &gt;/= 35% and HbA1c levels of &gt;/= 7% and &lt;/= 10.0%

          -  Subjects on antidiabetic therapy with fasting blood glucose levels of 100-200 mg/dL,
             hematocrit of &gt;/= 35%, and HbA1c levels of &gt;/= 6.5% and &lt;/= 9.0%

        Exclusion Criteria:

          -  Greater than 3 severe hypoglycemic episodes within six months of screen

          -  Pregnant, breastfeeding, or intends to become pregnant

          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT
             greater than 1.5 times the upper limit of normal

          -  History of hepatitis B surface antigen, hepatitis C antibody, or HIV

          -  Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy)

          -  Clinically significant and currently active diseases

          -  Clinically significant abnormalities in medical history, physical examination, or
             laboratory examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Ionis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <last_update_submitted>April 25, 2008</last_update_submitted>
  <last_update_submitted_qc>April 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isis Pharmaceuticals</name_title>
    <organization>Isis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Fasting plasma glucose</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

